



Fifth Business Restructuring Subsidy

July 7, 2022

We are pleased to inform you that, on June 9, 2022 we have received notification from the Small and Medium Enterprise Agency that we have been selected for the fifth round of subsidies for business restructuring.

- Title of the Project: New development towards pharmaceutical business field based on our technologies in research supporting service.
- Period of the Project: From the date of grant decision until March 31, 2023

<https://jigyousaikouchiku.go.jp/result.php>

GenAhead Bio. Inc is a biopharmaceutical company with proprietary nucleic acid delivery and genome editing technologies based on a wealth of experience. The genome-editing technology is applied to the treatment of intractable diseases. In addition, our genome-editing technology is used in the drug discovery research of pharmaceutical companies and bio-venture companies by producing disease model cells at a high rate through genetic transformation of normal cells. We are committed to the innovative healthcare business, and to the creation of a new innovation hub and are located in the Shonan Health Innovation Park, which is a center for innovative healthcare businesses and new innovations.

GenAhead Bio. Inc: <https://en.genaheadbio.co.jp/>

Shonan Health Innovation Park: <https://www.shonan-health-innovation-park.com/en>

For inquiries, please contact: info@genaheadbio.com